You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MSI-high Colorectal Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

Not yet recruiting
  • Colorectal Cancer
  • +3 more
  • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

Colorectal Carcinoma Trial in Guangzhou (Sintilimab, Oxaliplatin, capecitabine)

Recruiting
  • Colorectal Carcinoma
  • Guangzhou, China
    Sun Yat-sen University
Dec 29, 2022

Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))

Active, not recruiting
  • Colorectal Cancer
  • IBI310 (anti-CTLA-4 antibody)
  • Sintilimab(anti-PD-1 antibody)
  • Beijing, China
    Beijing cancer hospital
Sep 15, 2022

Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

Not yet recruiting
  • Colorectal Cancer Stage IV
  • +2 more
  • (no location specified)
Jun 19, 2022

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant

Recruiting
  • Colorectal Cancer
  • +3 more
  • Neoadjuvant therapy with PD-L1 inhibitor
  • Guangzhou, Guangdong, China
    the Third Affiliated Hospital of Sun Yat-Sen University
May 10, 2022

Metastatic Colorectal Cancer Trial in China (HX008, Investigator's Choice Chemotherapy)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • HX008
  • Investigator's Choice Chemotherapy
  • Hefei, Anhui, China
  • +9 more
Dec 8, 2022

Colorectal Cancer, Microsatellite Instability High Trial in Guangzhou (PD-1 inhibitor plus VEGF inhibitors)

Recruiting
  • Colorectal Cancer
  • Microsatellite Instability High
  • PD-1 inhibitor plus VEGF inhibitors
  • Guangzhou, Guangdong, China
    651 Dongfeng Road East
May 27, 2022

Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, MSI High Colorectal Cancer Trial in Boston (Nivolumab, Ipilimumab,

Recruiting
  • Microsatellite Stable Colorectal Cancer
  • +2 more
  • Boston, Massachusetts
    Massachusetts general Hospital
Mar 24, 2021

Colorectal Cancer Trial in China (Tislelizumab)

Recruiting
  • Colorectal Cancer
  • Bengbu, Anhui, China
  • +7 more
Sep 13, 2022

Colorectal Cancer Trial in Essen (Atezolizumab)

Recruiting
  • Colorectal Cancer
  • Essen, Germany
    Westdeutsches Tumorzentrum
Feb 14, 2022

MSI-H Colorectal Cancer Trial in Pittsburgh (Regorafenib, Pembrolizumab)

Not yet recruiting
  • MSI-H Colorectal Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Aug 17, 2023

Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H

Recruiting
  • Colorectal Cancer
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Oct 18, 2023

    Colorectal Tumors Trial in China (Pembrolizumab, Oxaliplatin, Leucovorin)

    Recruiting
    • Colorectal Neoplasms
    • Pembrolizumab
    • +6 more
    • Beijing, Beijing, China
    • +21 more
    Jan 25, 2023

    MSI-H Colorectal Cancer Trial (colorectal resection)

    Completed
    • MSI-H Colorectal Cancer
    • colorectal resection
    • (no location specified)
    May 22, 2023

    Malignancy, Malignant Tumor, Lymphoproliferative Disorders Trial in United Kingdom (Atezolizumab)

    Not yet recruiting
    • Malignancy
    • +8 more
    • Belfast, United Kingdom
    • +25 more
    Mar 14, 2023

    Gastric, Colorectal Adenocarcinoma Trial in Shenyang (tislelizumab)

    Not yet recruiting
    • Gastric
    • Colorectal Adenocarcinoma
    • Shenyang, Liaoning, China
      Liaoning Cancer Hospital & Institute
    Nov 1, 2023

    MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin Trial (Tislelizumab)

    Not yet recruiting
    • MSI-H Colorectal Cancer
    • +3 more
    • (no location specified)
    Apr 23, 2023

    MSI, dMMR Colorectal Cancer Trial in Paris (Monalizumab/MEDI5257)

    Not yet recruiting
    • MSI
    • dMMR Colorectal Cancer
    • Paris, France
      Department of medical oncology - Saint-Antoine Hospital
    Nov 28, 2023

    dMMR Colorectal Cancer Trial in Beijing (Cadonilimab)

    Recruiting
    • dMMR Colorectal Cancer
    • Beijing, Beijing, China
      National Cancer Center/Cancer Hospital, Chinese Academy of Medic
    Apr 13, 2023

    Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)

    Active, not recruiting
    Has Results
    • Colorectal Carcinoma
    • (no location specified)
    Oct 28, 2022

    MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma Trial in Spain (Spartalizumab)

    Active, not recruiting
    • MSI-H Colorectal Cancer
    • +30 more
    • Badalona, Barcelona, Spain
    • +9 more
    Oct 24, 2022

    Advanced Solid Tumor, Advanced/ Metastatic Renal Cell Carcinoma (RCC), Microsatellite Iinstability-high (MSI-H) or Mismatch

    Active, not recruiting
    • Advanced Solid Tumor
    • +3 more
    • TP-1454 monotherapy
    • TP-1454 combination therapy
    • Phoenix, Arizona
    • +8 more
    Nov 18, 2022

    Immunotherapy in MSI-H Metastatic Colorectal Cancer

    Recruiting
    • Colorectal Cancer
    • Carpi, Modena, Italy
      Ospedale Ramazzini
    Sep 5, 2022

    Colorectal Cancer Trial in Beijing (Fruquintinib and Sintilimab)

    Recruiting
    • Colorectal Cancer
    • Fruquintinib and Sintilimab
    • Beijing, Beijing, China
      Chinese Academy of Medical Sciences
    Jan 5, 2021